Raise closed, search for fresh raises on Seedstage

Jacksonville, FL

Development of antiviral treatment to address global respiratory viruses.

• Mission: TrippBio is focused on developing cost-effective antiviral treatments to address global respiratory viruses, such as COVID-19, RSV, and Influenza.  
• Innovation: The company’s flagship product, PanCytoVir™, is a host-directed, broad-spectrum antiviral therapy repurposing the drug probenecid, with promising preclinical and early-stage clinical results, including a successful Phase 2 trial for COVID-19.  
• Development Strategy: TrippBio leverages repurposed drugs to streamline drug development, reduce time and costs, and achieve faster market entry. This strategy helps mitigate risk while still addressing urgent public health needs.  
• Partnerships & Research: The company collaborates with leading research institutions, including the University of Georgia, to support the research and development of PanCytoVir™.  
• Clinical Progress: PanCytoVir™ has completed Phase 2 trials with encouraging results, and TrippBio is now preparing for Phase 3 trials and pursuing FDA approval.  
• Goal: TrippBio’s mission is to provide affordable, accessible antiviral treatments to combat respiratory viruses, with the aim of reaching global markets to address both immediate and long-term public health challenges.

TrippBio is raising funds to advance the development and regulatory approval of its innovative antiviral drug, PanCytoVir™, a treatment that targets respiratory viruses such as COVID-19, RSV, and Influenza. TrippBio focuses on repurposing existing drugs to address global health challenges swiftly and cost-effectively, aiming to meet the critical demand for effective antiviral treatments amid rising infectious disease threats. With promising early results in preclinical and clinical studies, including a successful Phase 2 trial for COVID-19, TrippBio intends to use this funding to support further clinical trials and regulatory engagements necessary for bringing PanCytoVir™ to market.

The company’s mission is rooted in providing accessible healthcare solutions by leveraging de-risked pharmaceuticals, which significantly reduce development time and costs. Partnering with leading research institutions, TrippBio has shown potential efficacy in PanCytoVir™ against multiple virus strains, positioning it as a versatile and essential treatment for respiratory viruses. This fundraising effort aims to propel TrippBio into the final stages of clinical trials, targeting FDA approval to eventually offer a safe, low-cost antiviral solution to a broad patient base worldwide.

Company Info

TrippBio, Inc. develops antiviral therapeutics for respiratory viruses, with PanCytoVir™ as its flagship product candidate.

TrippBio, Inc. is a biotechnology company focused on the development and commercialization of antiviral therapeutics targeting respiratory viruses such as COVID-19, influenza, and RSV. Its leading product candidate, PanCytoVir™, is a host-directed, broad-spectrum antiviral therapy based on the repurposed drug probenecid, which is known for its safety and efficacy in laboratory and early-stage clinical studies. PanCytoVir™ has completed Phase 2 clinical trials with encouraging results in COVID-19 patients, and the company is currently advancing discussions with the FDA to initiate Phase 3 trials.

TrippBio leverages established drug compounds to streamline the development process and reduce associated costs, allowing for potentially faster market entry compared to novel drug development. The company collaborates with institutions like the University of Georgia, where significant research backing PanCytoVir™ has been conducted, and has secured intellectual property rights to support its commercial strategy. TrippBio aims to meet the unmet need for affordable and effective treatments for respiratory viruses, addressing both immediate and long-term public health challenges.